Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

Lipid-Lowering Drugs

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

Clin Chem Lab Med.

Langlois MR, Nordestgaard BG, Langsted A, Chapman MJ, Aakre KM, Baum H, Borén J, Bruckert E, Catapano A, Cobbaert C, Collinson P, Descamps OS, Duff CJ, von Eckardstein A, Hammerer-Lercher A, Kamstrup PR, Kolovou G, Kronenberg F, Mora S, Pulkki K, Remaley AT, Rifai N, Ros E, Stankovic S, Stavljenic-Rukavina A, Sypniewska G, Watts GF, Wiklund O, Laitinen P, European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative.

doi: 10.1515/cclm-2019-1253.

RECOMMENDED

HypertensionLipid-Lowering DrugsThrombosis and Stroke

Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial

Lancet.

Gupta A, Mackay J, Whitehouse A, Godec T, Collier T, Pocock S, Poulter N, Sever P

doi: 10.1016/S0140-

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

JAMA Cardiol.

Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ

doi: 10.1001/

Lipid-Lowering Drugs

An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals

Eur Heart J Acute Cardiovasc Care.

Buonvino C, Chopard R, Guillon B, Puymirat E, Farnier M, Ferrières J, Krempf M, Bruckert E, Meneveau N, Schiele F

doi: 10.1177/2048872620912639.

Lipid-Lowering Drugs

Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

J Am Heart Assoc.

Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S

doi: 10.1161/JAHA.118.010932.

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?

JAMA Cardiol.

Lloyd-Jones DM

doi: 10.1001/

Lipid-Lowering Drugs

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome and without diabetes: Pooled data from 10 phase 3 trials

Diabetes Obes Metab.

Henry RR, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN

doi: 10.1111/dom.13273.

Lipid-Lowering Drugs

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis

JAMA Cardiol.

Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP

doi: 10.1001/jamacardio.2018.2258

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia

JAMA Cardiol.

Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, Ray KK, Flaim J, Ye Z, Catapano AL

doi: 10.1001/jamacardio.2020.2314.

Related content

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals

Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome and without diabetes: Pooled data from 10 phase 3 trials

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia